Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD)

Clinical Nephrology

Volumn 77, Issue 4, 2012, Pages 329-331

  Wilson, F Perry ^a   Berns, Jeffrey S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clearance; Continuous renal replacement therapy; Median inhibitory concentration; Pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ACUTE KIDNEY FAILURE; ARTICLE; BLOOD FLOW; CONTINUOUS HEMODIALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; MEDICAL STUDENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; KIDNEY FAILURE, CHRONIC; LENGTH OF STAY; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84861489948     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106993     Document Type: Article

References (8)

1. Rabindranath K, Adams J, Macleod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults Cochrane Database Syst Rev. 2007; 3: CD003773.
2. Boereboom FTJ, Ververs FFT, Blankestijn PJ, Savelkoul TJF, van Dijk A. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med. 1999; 25: 1100-1104. doi:10.1007/s001340051018 PubMed
3. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004; 58: 259-268. doi:10.1111/j.1365-2125.2004.02143.x PubMed
4. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42: 2398-2402. doi:10.1128/JCM.42.6.2398-2402.2004 PubMed
5. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007; 44: 1208-1215. doi:10.1086/513203 PubMed
6. Rybak M, Lomaestro B, Rotschafer JC, Moellering, R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health-Syst Pharm. 2009; 66: 82-98.
7. Augustine JJ, Sandy D, Seifert TH, Paganini EP. A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF. Am J Kidney Dis. 2004; 44: 1000-1007. doi:10.1053/j.ajkd.2004.08.022 PubMed
8. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P; VA/NIH Acute Renal Failure Trial Network. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008; 359: 7-20. doi:10.1056/NEJMoa0802639 PubMed